The FDA has granted Motif Neurotech approval to begin human trials of its Motif XCS System, a brain implant aimed at treatment‑resistant depression. The RESONATE study will follow patients for a year ...
Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.
Motif Neurotech announced today that it received FDA investigational device exemption (IDE) to evaluate its brain stimulation ...
Motif Neurotech, a brain-computer interface (BCI) company developing technologies for mental health, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational ...
While we focused solely on its encryption and content filtering capabilities for this review, please note that the XCS 570 offers a host of other features to help control the flow of data in and out ...
The FDA has authorized Motif Neurotech to begin clinical testing of its brain implant aimed at adults with treatment-resistant depression. The RESONATE study will assess safety, symptom improvement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results